Gene Therapy for Noninfectious Uveitis

REFERENCES

• Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica. 2004;218(4):223–236.
   PubMed Web of Science ®Google Scholar
• Chiang YP, Bassi LJ, Javitt JC. Federal budgetary costs of blindness. Milbank Q. 1992;70(2):319–340.
   PubMed Web of Science ®Google Scholar
• Gritz D. Incidence and prevalence of uveitis in Northern California: The Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111(3):491–500.
   PubMed Web of Science ®Google Scholar
• Schewitz-Bowers LP, Lee RW, Dick AD. Immune mechanisms of intraocular inflammation. Ex Rev Op. 2010;5(1):43–58.
   Google Scholar
• Murphy CC, Greiner K, Plskova J, Frost NA, Forrester JV, Dick AD. Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. Br J Ophthalmol. 2007;91(2):154–156.
   PubMed Web of Science ®Google Scholar
• Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18(6):481–486.
   PubMed Web of Science ®Google Scholar
• Rothova A, Berendschot TTJM, Probst K, van Kooij B, Baarsma GS. Birdshot chorioretinopathy: long-term manifestations and visual prognosis. Ophthalmology. 2004;111(5):954–959.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373–380.
   PubMed Web of Science ®Google Scholar
• Sharma SM, Nestel AR, Lee RWJ, Dick AD. Clinical review: anti-TNFα therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm. 2009;17(6):403–414.
   PubMed Web of Science ®Google Scholar
• Bainbridge JWB, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber’scongenital amaurosis. N Engl J Med. 2008;358(21):2231–2239.
   PubMed Web of Science ®Google Scholar
• Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA. 2008;105(39):15112–15117.
   PubMed Web of Science ®Google Scholar
• Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med. 2008;358(21):2240–2248.
   PubMed Web of Science ®Google Scholar
• Agarwal RK, Caspi RR. Rodent models of experimental autoimmune uveitis. Methods Mol Med. 2004;102:395–419.
   PubMedGoogle Scholar
• Trittibach P, Barker SE, Broderick CA, et al. Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis. Gene Ther. 2008;15(22):1478–1488.
   PubMed Web of Science ®Google Scholar
• Fang I-M, Lin C-P, Yang C-H, et al. Inhibition of experimental autoimmune anterior uveitis by adenovirus-mediated transfer of the interleukin-10 gene. J Ocul Pharmacol Ther. 2005;21(6):420–428.
   PubMed Web of Science ®Google Scholar
• Broekhuyse RM, Kuhlmann ED, Winkens HJ, Van Vugt AH. Experimental autoimmune anterior uveitis (EAAU), a new form of experimental uveitis, I:induction by a detergent-insoluble, intrinsic protein fraction of the retinal pigment epithelium. Exp Eye Res. 1991;52(4):465–474.
   PubMed Web of Science ®Google Scholar
• Bora NS, Sohn J-H, Kang S-G, et al. Type I collagen is the autoantigen in experimental autoimmune anterior uveitis. J Immunol. 2004;172(11):7086–7094.
   PubMed Web of Science ®Google Scholar
• Zinkernagel MS, McMenamin PG, Forrester JV, Degli-Esposti MA. T cell responses in experimental viral retinitis: mechanisms, peculiarities and implications for gene therapy with viral vectors. Progr Retinal Eye Res. 2011;30(4):275–284.
   PubMed Web of Science ®Google Scholar
• Ali RR. Ocular gene therapy: introduction to the special issue. Gene Ther. 2012;19(2):119–120.
   PubMed Web of Science ®Google Scholar
• Kowalczuk L, Touchard E, Camelo S, et al. Local ocular immunomodulation resulting from electrotransfer of plasmid encoding soluble TNF receptors in the ciliary muscle. Invest Ophthalmol Visual Sci. 2009;50(4):1761–1768.
   PubMed Web of Science ®Google Scholar
• Bloquel C. Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-α soluble receptor in uveitis. FASEB J. 2006;20(2):389–391.
   PubMed Web of Science ®Google Scholar
• deKozak Y, Thillaye-Goldenberg B, Naud M-C, Da Costa AV, Auriault C, Verwaerde C. Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus-mediated transfer of the viral IL-10 gene. Clin Exp Immunol. 2002;130(2):212–223.
   PubMed Web of Science ®Google Scholar
• Petrs-Silva H, Dinculescu A, Li Q, et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Therapy. 2008;17(3):463–471.
   PubMed Web of Science ®Google Scholar
• Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 2008;21(4):583.
   PubMed Web of Science ®Google Scholar
• Henckaerts E, Linden RM. Adeno-associated virus: a key to the human genome? Future Virol. 2010;5(5):555.
   PubMed Web of Science ®Google Scholar
• Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther. 2010;17(3):295.
   PubMed Web of Science ®Google Scholar
• Buie LK, Rasmussen CA, Porterfield EC, et al. Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys. Invest Ophthalmol Visual Sci. 2010;51(1):236–248.
   PubMed Web of Science ®Google Scholar
• Barker SE, Broderick CA, Robbie SJ, et al. Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice. J Gene Med. 2009;11(6):486–497.
   PubMed Web of Science ®Google Scholar
• Li Q, Miller R, Han P-Y, et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis. 2008;14:1760–1769.
   PubMed Web of Science ®Google Scholar
• Sonoda K-H, Sakamoto T, Qiao H, et al. The analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: vitreous cavity-associated immune deviation. Immunology. 2005;116(3):390–399.
   PubMed Web of Science ®Google Scholar
• Denniston AK, Tomlins P, Williams GP, et al. Aqueous humor suppression of dendritic cell function helps maintain immune regulation in the eye during human uveitis. Invest Ophthalmol Visual Sci. 2012;53(2):888–896.
   PubMed Web of Science ®Google Scholar
• Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associatedvirus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21(6):704–712.
   PubMed Web of Science ®Google Scholar
• Dick AD, Carter D, Robertson M, et al. Control of myeloid activity during retinal inflammation. J Leukocyte Biol. 2003;74(2):161–166.
   PubMed Web of Science ®Google Scholar
• Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170–181.
   PubMed Web of Science ®Google Scholar
• Pot C, Apetoh L, Kuchroo VK. Type 1 regulatory T cells (Tr1) in autoimmunity. SeminImmunol. 2011;23(3):202–208.
   Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol.2001;19:683–765.
   PubMed Web of Science ®Google Scholar
• Calder CJ, Nicholson LB, Dick AD. A selective role for the TNF p55 receptor in autocrine signaling following IFN-gamma stimulation in experimental autoimmune uveoretinitis. J Immunol. 2005;175(10):6286–6293.
   PubMed Web of Science ®Google Scholar
• Calder VL, Shaer B, Muhaya M, et al. Increased CD4+ expression and decreased IL-10 in the anterior chamber in idiopathic uveitis. Invest Ophthalmol Visual Sci. 1999;40(9):2019–2024.
   PubMed Web of Science ®Google Scholar
• Sun B, Sun SH, Chan CC, Caspi RR. Evaluation of in vivo cytokine expression in EAU-susceptible and resistant rats: a role for IL-10 in resistance? Exp Eye Res. 2000;70(4):493–502.
   PubMed Web of Science ®Google Scholar
• Kerr EC, Copland DA, Dick AD, Nicholson LB. The dynamics of leukocyte infiltration in experimental autoimmune uveoretinitis. Progr Retinal Eye Res. 2008;27(5):527–535.
   PubMed Web of Science ®Google Scholar
• Rizzo LV, Xu H, Chan CC, Wiggert B, Caspi RR. IL-10 has a protective role in experimental autoimmune uveoretinitis. Int Immunol. 1998;10(6):807–814.
   PubMed Web of Science ®Google Scholar
• Broderick CA, Smith AJ, Balaggan KS, et al. Local administration of an adeno-associated viral vector expressing IL-10 reduces monocyte infiltration and subsequent photoreceptor damage during experimental autoimmune uveitis. Mol Ther. 2005;12(2):369–373.
   PubMed Web of Science ®Google Scholar
• Smith JR, Verwaerde C, Rolling F, et al. Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoimmune uveoretinitis. Hum Gene Ther. 2005;16(9):1037–1046.
   PubMed Web of Science ®Google Scholar
• Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Progr Retinal Eye Res. 2004;23(6):617–637.
   PubMed Web of Science ®Google Scholar
• Khera TK, Dick AD, Nicholson LB. Mechanisms of TNF-alpha: regulation in uveitis: focus on RNA-binding proteins. Progr Retinal Eye Res. 2010;29(6):610–621.
   PubMed Web of Science ®Google Scholar
• Khera TK, Copland DA, Boldison J, et al. Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis. Clin Exp Immunol. 2012;168(2):165–177.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Duncan L, Forrester JV, Dick AD. Systemic CD4(+) T cell phenotype and activation status in intermediate uveitis. Br J Ophthalmol. 2004;88(3):412–416.
   PubMed Web of Science ®Google Scholar
• Raveney BJE, Copland DA, Dick AD, Nicholson LB. TNFR1-dependent regulation of myeloid cell function in experimental autoimmune uveoretinitis. J Immunol. 2009;183(4):2321–2329.
   PubMed Web of Science ®Google Scholar
• Dick AD, McMenamin PG, Körner H, et al. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol. 1996;26(5):1018–1025.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT. Future for biological therapy for uveitis. Curr Opin Ophthalmol. 2010;21(6):473–477.
   PubMed Web of Science ®Google Scholar
• Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001;57(10):1885–1888.
   PubMed Web of Science ®Google Scholar
• Wu L, Hernandez-Bogantes E, Roca JA, Arevalo JF, Barraza K, Lasave AF. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina (Philadelphia, Pa.). 2011;31(2):298–303.
   PubMed Web of Science ®Google Scholar
• Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P. Intravitreal adalimumab for refractory uveitis-related macular edema. OPHTHA. 2010;117(8):1612–1616.
   PubMed Web of Science ®Google Scholar
• Touchard E, Bloquel C, Bigey P, et al. Effects of ciliary muscle plasmid electrotransfer of TNF-alpha soluble receptor variants in experimental uveitis. Gene Ther. 2009;16(7):862–873.
   PubMed Web of Science ®Google Scholar
• Zhang X, Jin J, Tang Y, Speer D, Sujkowska D, Markovic-Plese S. IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J Immunol. 2009;182(6):3928–3936.
   PubMed Web of Science ®Google Scholar
• Plskova J, Greiner K, Muckersie E, Duncan L, Forrester JV. Interferon-alpha: a key factor in autoimmune disease? Invest Ophthalmol Visual Sci. 2006;47(9):3946–3950.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Kotter I, Gunaydin I, Stubiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93(7):906–913.
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91(3):335–339.
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractoryBehcetuveitis. Arch Ophthalmol. 2011;129(3):288.
   Google Scholar
• Tian L, Yang P, Lei B, et al. AAV2-mediated subretinal gene transfer of hIFN-α attenuates experimental autoimmune uveoretinitis in mice. PLoS ONE. 2011;6(5):e19542.
   Web of Science ®Google Scholar
• Kertes PJ, Britton WA, Leonard BC. Intravitreal interferon alpha-2b for the treatment of neovascular age-related macular degeneration: a pilot study. Can J Ophthalmol. 1997;32(3):185–188.
   PubMed Web of Science ®Google Scholar
• Porter R. Uveitis in association with multiple sclerosis. Br J Ophthalmol. 1972;56(6):478–481.
   PubMed Web of Science ®Google Scholar
• Becker MD. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol. 2005;89(10):1254–1257.
   PubMed Web of Science ®Google Scholar
• Wong J, Gomes T, Mamdani M, Manno M, O’Connor PW. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. Can J Neurol Sci. 2011;38(3):429–433.
   PubMed Web of Science ®Google Scholar
• Shih C-S, Laurie N, Holzmacher J, et al. AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models. Neuromolecular Med. 2009;11(1):43–52.
   PubMed Web of Science ®Google Scholar
• Luna JD, Chan CC, Derevjanik NL, et al. Blood–retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J Neurosci Res. 1997;49(3):268–280.
   PubMed Web of Science ®Google Scholar
• Hu D-N, Chen M, Zhang DY, Ye F, McCormick SA, Chan C-C. Interleukin-1β increases baseline expression and secretion of interleukin-6 by human uveal melanocytes in vitro via p38 MAPK/NFκB pathway. Invest OphthalmolVisual Sci. 2011;52(6):3767–3774.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Ikeda U, Shimada K, Minota S, Kano S. Regulation of ICAM-1 expression by inflammatory cytokines in rat mesangial cells. Cytokine. 1996;8(2):109–114.
   PubMed Web of Science ®Google Scholar
• Arend WP. The balance between IL-1 and IL-1Ra in disease.Cytokine Growth Factor Rev. 2002;13(4–5):323–340.
   PubMed Web of Science ®Google Scholar
• Teoh SCB, Sharma S, Hogan A, Lee R, Ramanan AV, Dick AD. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol. 2007;91(2):263–264.
   PubMed Web of Science ®Google Scholar
• Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA. Resistant Behçet disease responsive to anakinra. Ann Intern Med. 2008;149(4):284–286.
   PubMed Web of Science ®Google Scholar
• Lim W-K, Fujimoto C, Ursea R, et al. Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration. Arch Ophthalmol. 2005;123(7):957–963.
   PubMedGoogle Scholar
• Stein-Streilein J, Taylor AW. An eye’s view of T regulatory cells. J Leukocyte Biol. 2006;81(3):593–598.
   PubMed Web of Science ®Google Scholar
• Li D, Taylor AW. Diminishment of alpha-MSH anti-inflammatory activity in MC1r siRNA-transfected RAW264.7 macrophages. J Leukocyte Biol. 2008;84(1):191–198.
   PubMed Web of Science ®Google Scholar
• Lee DJ, Biros DJ, Taylor AW. Injection of an alpha-melanocyte stimulating hormone expression plasmid is effective in suppressing experimental autoimmune uveitis. IntImmunopharmacol. 2009;9(9):1079–1086.
   PubMed Web of Science ®Google Scholar
• Chan CC, Li Y, Sun B, et al. Recombinant adenovirus encoding gp100 modulates experimental melanin-protein induced uveitis (EMIU). J Autoimmun. 1998;11(2):111–118.
   PubMed Web of Science ®Google Scholar
• Agarwal RK, Kang Y, Zambidis E, Scott DW, Chan CC, Caspi RR. Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest. 2000;106(2):245–252.
   PubMed Web of Science ®Google Scholar
• Copland DA, Wertheim MS, Armitage WJ, Nicholson LB, Raveney BJE, Dick AD. The clinical time-course of experimental autoimmune uveoretinitis using topical endoscopic fundal imaging with histologic and cellular infiltrate correlation. Invest Ophthalmol Visual Sci. 2008;49(12):5458–5465.
   PubMed Web of Science ®Google Scholar
• Chen M, Copland DA, Zhao J, et al. Persistent inflammation subverts thrombospondin-1-induced regulation of retinal angiogenesis and is driven by CCR2 ligation. Am J Pathol. 2012;180(1):235–245.
   PubMed Web of Science ®Google Scholar
• Pennesi G, Mattapallil MJ, Sun S-H, et al. A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice. J Clin Invest. 2003;111(8):1171–1180.
   PubMed Web of Science ®Google Scholar
• Lambe T, Leung JCH, Ferry H, et al. Limited peripheral T cell anergy predisposes to retinal autoimmunity. J Immunol. 2007;178(7):4276–4283.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Plüddemann A, Hoe JC, et al. Immune inhibitory ligand CD200 induction by TLRs and NLRs limits macrophage activation to protect the host from meningococcal septicemia. Cell Host Microbe. 2010;8(3):236–247.
   PubMed Web of Science ®Google Scholar
• Novosad BD, Astley RA, Callegan MC. Role of Toll-like receptor (TLR) 2 in experimental Bacillus cereusendophthalmitis. PLoS ONE. 2011;6(12):e28619.
   PubMed Web of Science ®Google Scholar
• Denniston AK, Kottoor SH, Khan I, et al. Endogenous cortisol and TGF-beta in human aqueous humor contribute to ocular immune privilege by regulating dendritic cell function. J Immunol. 2011;186(1):305–311.
   PubMed Web of Science ®Google Scholar
• Tran DQ. TGF-β: the sword, the wand, and the shield of FOXP3+ regulatory T cells. J Mol Cell Biol. 2012;4(1):29–37.
   PubMed Web of Science ®Google Scholar
• Ohta K, Wiggert B, Yamagami S, Taylor AW, Streilein JW. Analysis of immunomodulatory activities of aqueous humor from eyes of mice with experimental autoimmune uveitis. J Immunol. 2000;164(3):1185–1192.
   PubMed Web of Science ®Google Scholar
• Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity. 2006;25(3):455–471.
   PubMed Web of Science ®Google Scholar
• Haruta H, Ohguro N, Fujimoto M, et al. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Visual Sci. 2011;52(6):3264–3271.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677–686.
   PubMed Web of Science ®Google Scholar
• Erwig LP, Kluth DC, Walsh GM, Rees AJ. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J Immunol. 1998;161(4):1983–1988.
   PubMed Web of Science ®Google Scholar
• Erwig LP, Stewart K, Rees AJ. Macrophages from inflamed but not normal glomeruli are unresponsive to anti-inflammatory cytokines. Am J Pathol. 2000;156(1):295–301.
   PubMed Web of Science ®Google Scholar
• Simon D, Denniston AKO, Tomlins PJ, et al. Soluble gp130, an antagonist of IL-6 transsignaling, is elevated in uveitis aqueous humor. Invest Ophthalmol Visual Sci. 2008;49(9):3988–3991.
   PubMed Web of Science ®Google Scholar
• Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA. 1986;83(12):4167–4171.
   PubMed Web of Science ®Google Scholar
• Varin A, Gordon S. Alternative activation of macrophages: immune function and cellular biology. Immunobiology. 2009;214(7):630–641.
   PubMed Web of Science ®Google Scholar
• Caspi RR. Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol. 2002;21(2–3):197–208.
   Google Scholar
• Fenton MJ, Buras JA, Donnelly RP. IL-4 reciprocally regulates IL-1 and IL-1 receptor antagonist expression in human monocytes. J Immunol. 1992;149(4):1283–1288.
   PubMed Web of Science ®Google Scholar
• Cheung DL, Hart PH, Vitti GF, Whitty GA, Hamilton JA. Contrasting effects of interferon-gamma and interleukin-4 on the interleukin-6 activity of stimulated human monocytes. Immunology. 1990;71(1):70–75.
   PubMed Web of Science ®Google Scholar
• Lee YS, Amadi-Obi A, Yu C-R, Egwuagu CE. Retinal cells suppress intraocular inflammation (uveitis) through production of interleukin-27 and interleukin-10. Immunology. 2011;132(4):492–502.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, de Kozak Y, Saoudi A, et al. Recombinant IL-4 aggravates experimental autoimmune uveoretinitis in rats. J Immunol. 1996;157(5):2209–2215.
   PubMed Web of Science ®Google Scholar
• Lee SI, Kwon HJ, Lee E-S, et al. Using pCIN-mIL-4 DNA vector to express mRNA and protein and to improve herpes simplex virus-induced Behcet’s disease symptoms in mice. Vaccine. 2007;25(41):7047–7055.
   PubMed Web of Science ®Google Scholar
• Dick AD, Broderick C, Forrester JV, Wright GJ. Distribution of OX2 antigen and OX2 receptor within retina. Invest Ophthalmol Visual Sci. 2001;42(1):170–176.
   PubMed Web of Science ®Google Scholar
• Broderick C, Hoek RM, Forrester JV, Liversidge J, Sedgwick JD, Dick AD. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am J Pathol. 2002;161(5):1669–1677.
   PubMed Web of Science ®Google Scholar
• Banerjee D, Dick A. Blocking CD200-CD200 receptor axis augments NOS-2 expression and aggravates experimental autoimmune uveoretinitis in Lewis rats. OculImmunolInflamm. 2004;12(2):115–125.
   Google Scholar
• Copland DA, Calder CJ, Raveney BJE, et al. Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am J Pathol. 2007;171(2):580–588.
   PubMed Web of Science ®Google Scholar
• Lee RWJ, Dick AD. Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Eye (Lond). 2012;26(1):17–28.
   PubMed Web of Science ®Google Scholar
• Natkunarajah M, Trittibach P, McIntosh J, et al. Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2/8. Gene Ther. 2008;15(6):463–467.
   PubMed Web of Science ®Google Scholar
• Tsai M-L, Horng C-T, Chen S-L, Xiao X, Wang C-H, Tsao Y-P. Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist. Mol Vis. 2009;15:1542–1552.
   PubMed Web of Science ®Google Scholar
• Balaggan KS, Ali RR. Ocular gene delivery using lentiviral vectors.Gene Ther. 2012;19(2):145–153.
   PubMed Web of Science ®Google Scholar
• Verwaerde C, Naud M-C, Delanoye A, et al. Ocular transfer of retinal glial cells transduced ex vivo with adenovirus expressing viral IL-10 or CTLA4-Ig inhibits experimental autoimmune uveoretinitis. Gene Ther. 2003;10(23):1970–1981.
   PubMed Web of Science ®Google Scholar